Michigan
Quiénes somos
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Estudio de INCB099280 en combinación con adagrasib en adultos con tumores sólidos avanzados portadores de una mutación en KRASG12C.
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
Prueba de la adición de la terapia ablativa total al tratamiento sistémico habitual para el cáncer colorrectal metastásico limitado, el estudio ERASur
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Immunotherapy for Third Line Metastatic Colorectal Cancer
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
